"Although this has yet to be demonstrated in humans, we believe that the mechanism we have identified constitutes a very interesting therapeutic target because it is not limited to slowing down the progression of the disease, but also allows certain cognitive functions to be partially restored," explains the person in charge of the study, Yves de Koninck, a professor in the Faculty of Medicine and researcher at Laval University.
The mechanism that enables this progress revolves around a transporter in the brain called KCC2. A previous study had shown that levels of the KCC2 transporter were lower in deceased Alzheimer's patients.
The molecule created by the researchers, CLP290, is a KCC2 activator that prevents its reduction.
